AI 'Zhiliao Doctor' aims to ease anxiety in breast cancer patients on CDK4/6 inhibitors
NCT ID NCT07409298
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This trial tests whether an AI-based management platform, called 'Zhiliao Doctor,' can reduce anxiety and depression in 300 breast cancer patients taking CDK4/6 inhibitors at home. Participants are randomly assigned to standard care, the AI platform, or personalized follow-up calls. The study measures changes in mood, quality of life, and medication adherence over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Zhiliao Doctor AI management platform (device) and tailored active follow-up (behavioral intervention)
What this could lead to
If successful, this could show that AI-based support helps breast cancer patients feel less anxious and depressed while managing their treatment at home.
What could go wrong
This is a relatively small, early-stage trial focused on psychological outcomes, not survival. The AI platform may not significantly improve mental health, and results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Tianjin Medical University Cancer Institute & Hospital
Tianjin, 300000, China